Core Viewpoint - The innovative drug sector has shown strong performance in the first half of the year, driven by successful collaborations, excellent clinical data, and supportive policies, despite recent declines in various indices related to the sector [1]. Group 1: Market Performance - The Hang Seng Hong Kong Stock Connect Innovative Drug Index fell by 4.4% [1] - The CSI Innovative Drug Industry Index decreased by 4.2% [1] - The CSI Biotechnology Theme Index dropped by 4.1% [1] - The CSI Pharmaceutical and Health Comprehensive Index declined by 4% [1] - The CSI Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index fell by 3.9% [1] - The Everbright Innovative Drug ETF (159316) saw a net subscription of 116 million shares today [1] Group 2: Sector Insights - The innovative drug sector is expected to rapidly realize commercial value for newly launched products due to national policies encouraging innovation [1] - The proportion of domestic innovative drugs in hospital products is anticipated to increase quickly, positioning it as one of the best growth segments [1]
医药板块集体回调，恒生创新药ETF（159316）逆势获近1.2亿份净申购
Sou Hu Cai Jing·2025-09-04 13:28